MultivisionDx, a Finnish startup developing AI tools for personalized cancer diagnostics, has raised a €1 million pre-seed round to continue developing its spatial biology diagnostics platform for cancer treatment decision support. The round was led by Antler, with participation from Helsinki University Funds, Kaikarhenni Oy, and a Finnish healthcare angel investor.
About MultivisionDx
-
MultivisionDx is a Finnish healthtech company founded in 2025 to bring advances in spatial biology and computer vision into clinical cancer diagnostics. The technology was developed at the University of Helsinki and is based on research that identifies spatial tumor signatures to support treatment decision-creating.
-
MultivisionDx develops AI-powered decision-support tools that analyze tumor biology and the tumor microenvironment to assist clinicians assess disease aggressiveness and tailor therapies for patients with solid cancers.
“This investment enables us to shift from scientific discovery to clinical impact. Our mission is to turn complex biology into actionable diagnostics that guide treatment decisions. With this investment, we will advance our first products into validation. Over the next 18 months, our goal is to demonstrate that spatial biology can shift from research to routine diagnostics – and fundamentally improve how cancer therapy decisions are built,” declares Michael Wittinger, CEO of MultivisionDx.
Investment details
The round was led by Antler, with participation from Helsinki University Funds, Kaikarhenni Oy, and a Finnish healthcare angel investor.
-
Antler is a global early-stage venture capital firm that invests in founders at the earliest stages of company creation. Operating across more than 30 cities worldwide, Antler supports startups from inception by providing initial funding and access to a global founder network.
-
Its CEE portfolio includes Finnish search engine Klu, Lithuanian marketplace Traxlo, Finnish startup QMill, Finnish e-commerce Daze, and many others.
The investment will be utilized to accelerate the development of MultivisionDx proprietary diagnostic tests, and will enable the completion of key validation studies, formalizing strategic partnerships with international stakeholders, and raising additional public funding.
Read more: Finnish cleantech Filtrabit raised €2M to expand industrial dust separation technology internationally
Leave a Reply